<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384553</url>
  </required_header>
  <id_info>
    <org_study_id>OSHO #071</org_study_id>
    <nct_id>NCT00384553</nct_id>
  </id_info>
  <brief_title>Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma</brief_title>
  <official_title>Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <brief_summary>
    <textblock>
      This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose
      chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or
      refractory aggressive Non- Hodgkins's Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and
      cisplatin followed by high dose chemotherapy with treosulfan, etoposide and cisplatin (TEC)
      an autologous peripheral blood stem cell transplantation(aPBSCT). In case of only partial
      remission a second identical high dose chemotherapy and aPBSCT follows. Patients with primary
      refractory disease or early relapse within 6 months should receive a allogenous stem cell
      transplantation. For Patients with CD 20 positive B-cell lymphoma the chemotherapy regiments
      DHAP and TEC are combined with rituximab.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <completion_date>June 2010</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>remission rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHAP</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEC</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage
             I-IV

          -  pretreatment with systemic therapy

          -  18-65 years of age

          -  Performance status:ECOG 0-2

               -  Granulocyte count &gt;1.5/µm3, Platelet count &gt;100/µm3

               -  Creatinine -Clearance ≥ 1 ml/sec

               -  GPT/GOT ≤ 1.5 x normal (except tumour related)

               -  Bilirubine &lt; 22 µmol/l

          -  no participation in another study 3 month before and during this study −informed
             consent

        Exclusion Criteria:

          -  Second neoplasia in history or existing except basalioma or squamous epithelium
             carcinoma of the skin or removed cervical intraepithelial neoplasia

          -  CNS- involvement by lymphoma

               -  respiratory Partial- or global insufficiency

               -  cardiac insufficiency (NYHA-Stage 3-4, EF &lt; 30 %)

               -  severe neurological or psychiatric disease

               -  pregnancy

          -  HIV positivity ,active virus hepatitis, bacterial infection − No follow up procedures
             ensured
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Koenigsmann, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Magdeburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Koenigsmann, PD Dr. med</last_name>
    <phone>+4939113281</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Koenigsmann, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>October 5, 2006</last_update_submitted>
  <last_update_submitted_qc>October 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

